Literature DB >> 22241045

The effect of iron availability on transcription of the Neisseria meningitidis fHbp gene varies among clonal complexes.

Holly Sanders1, Carina Brehony2, Martin C J Maiden2, Caroline Vipond1, Ian M Feavers1.   

Abstract

Factor H binding protein (fHbp) is a major antigenic component of novel vaccines designed to protect against meningococcal disease. Prediction of the potential coverage of these vaccines is difficult, as fHbp is antigenically variable and levels of expression differ among isolates. Transcriptional regulation of the fHbp gene is poorly understood, although evidence suggests that oxygen availability is involved. In this study iron accessibility was found to affect fHbp transcription. However, regulation differed among meningococcal clonal complexes (ccs). For the majority of isolates, increased iron concentrations upregulated transcription. This effect was enhanced by the presence of a 181 bp insertion element upstream of fHbp, associated with isolates belonging to cc4 and cc5. Conversely, meningococci belonging to cc32 showed iron-repressed control of fHbp, as regulation was dominated by cotranscription with the iron-repressed upstream gene cbbA. These results highlight the complexity of fHbp regulation and demonstrate that control of transcription can vary among genetic lineages.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22241045      PMCID: PMC3949423          DOI: 10.1099/mic.0.054957-0

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  33 in total

1.  ABC of meningococcal diversity.

Authors:  I M Feavers
Journal:  Nature       Date:  2000-03-30       Impact factor: 49.962

2.  The role of Eh, pH and iron in the bactericidal power of human plasma.

Authors:  J J Bullen; P B Spalding; C G Ward; H J Rogers
Journal:  FEMS Microbiol Lett       Date:  1992-07-01       Impact factor: 2.742

3.  A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.

Authors:  Oliver Koeberling; Isabel Delany; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

4.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

Review 5.  Iron acquisition in the pathogenic Neisseria.

Authors:  C A Genco; P J Desai
Journal:  Trends Microbiol       Date:  1996-05       Impact factor: 17.079

6.  Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37.

Authors:  K L Seib; D Serruto; F Oriente; I Delany; J Adu-Bobie; D Veggi; B Aricò; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

Review 7.  Iron transport systems in Neisseria meningitidis.

Authors:  Donna Perkins-Balding; Melanie Ratliff-Griffin; Igor Stojiljkovic
Journal:  Microbiol Mol Biol Rev       Date:  2004-03       Impact factor: 11.056

8.  Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B.

Authors:  Renata Grifantini; Shite Sebastian; Elisabetta Frigimelica; Monia Draghi; Erika Bartolini; Alessandro Muzzi; Rino Rappuoli; Guido Grandi; Caroline Attardo Genco
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-25       Impact factor: 11.205

9.  Mechanism of oxygen sensing by the bacterial transcription factor fumarate-nitrate reduction (FNR).

Authors:  Jason Crack; Jeffrey Green; Andrew J Thomson
Journal:  J Biol Chem       Date:  2003-11-25       Impact factor: 5.157

10.  Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870.

Authors:  Vega Masignani; Maurizio Comanducci; Marzia Monica Giuliani; Stefania Bambini; Jeannette Adu-Bobie; Beatrice Arico; Brunella Brunelli; Alessandro Pieri; Laura Santini; Silvana Savino; Davide Serruto; David Litt; Simon Kroll; Jo Anne Welsch; Dan M Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more
  11 in total

1.  Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.

Authors:  Massimiliano Biagini; Marco Spinsanti; Gabriella De Angelis; Sara Tomei; Ilaria Ferlenghi; Maria Scarselli; Fabio Rigat; Nicola Messuti; Alessia Biolchi; Alessandro Muzzi; Giulia Anderloni; Brunella Brunelli; Elena Cartocci; Francesca Buricchi; Chiara Tani; Maria Stella; Monica Moschioni; Elena Del Tordello; Annalisa Colaprico; Silvana Savino; Marzia M Giuliani; Isabel Delany; Mariagrazia Pizza; Paolo Costantino; Nathalie Norais; Rino Rappuoli; Vega Masignani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-17       Impact factor: 11.205

2.  Neisseria meningitidis Urethritis Outbreak Isolates Express a Novel Factor H Binding Protein Variant That Is a Potential Target of Group B-Directed Meningococcal (MenB) Vaccines.

Authors:  Yih-Ling Tzeng; Serena Giuntini; Zachary Berman; Soma Sannigrahi; Dan M Granoff; David S Stephens
Journal:  Infect Immun       Date:  2020-11-16       Impact factor: 3.441

Review 3.  Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.

Authors:  Lisa K McNeil; Robert J Zagursky; Shuo L Lin; Ellen Murphy; Gary W Zlotnick; Susan K Hoiseth; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

4.  The role of apolipoprotein N-acyl transferase, Lnt, in the lipidation of factor H binding protein of Neisseria meningitidis strain MC58 and its potential as a drug target.

Authors:  R A G da Silva; C P Churchward; A V Karlyshev; O Eleftheriadou; A K Snabaitis; M R Longman; A Ryan; R Griffin
Journal:  Br J Pharmacol       Date:  2016-12-21       Impact factor: 8.739

Review 5.  Recent Progress in the Prevention of Serogroup B Meningococcal Disease.

Authors:  Ian M Feavers; Martin C J Maiden
Journal:  Clin Vaccine Immunol       Date:  2017-05-05

6.  Clustered intergenic region sequences as predictors of factor H Binding Protein expression patterns and for assessing Neisseria meningitidis strain coverage by meningococcal vaccines.

Authors:  Caroline Cayrou; Ayodeji A Akinduko; Evgeny M Mirkes; Jay Lucidarme; Stephen A Clark; Luke R Green; Helen J Cooper; Julie Morrissey; Ray Borrow; Christopher D Bayliss
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

7.  Variant Signal Peptides of Vaccine Antigen, FHbp, Impair Processing Affecting Surface Localization and Antibody-Mediated Killing in Most Meningococcal Isolates.

Authors:  Ronni A G da Silva; Andrey V Karlyshev; Neil J Oldfield; Karl G Wooldridge; Christopher D Bayliss; Ali Ryan; Ruth Griffin
Journal:  Front Microbiol       Date:  2019-12-19       Impact factor: 5.640

8.  Deconvolution of intergenic polymorphisms determining high expression of Factor H binding protein in meningococcus and their association with invasive disease.

Authors:  Marco Spinsanti; Tarcisio Brignoli; Margherita Bodini; Lucia Eleonora Fontana; Matteo De Chiara; Alessia Biolchi; Alessandro Muzzi; Vincenzo Scarlato; Isabel Delany
Journal:  PLoS Pathog       Date:  2021-03-26       Impact factor: 6.823

9.  Phase variation of PorA, a major outer membrane protein, mediates escape of bactericidal antibodies by Neisseria meningitidis.

Authors:  Isfahan Tauseef; Youssif M Ali; Christopher D Bayliss
Journal:  Infect Immun       Date:  2013-02-12       Impact factor: 3.441

Review 10.  Biological Functions of the Secretome of Neisseria meningitidis.

Authors:  Jan Tommassen; Jesús Arenas
Journal:  Front Cell Infect Microbiol       Date:  2017-06-16       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.